CCM
JSPR icon

Coldstream Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Coldstream Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38
Closed -$164 – 2251
2025
Q1 		$164 Buy
+38
New +$253 ﹤0.01% 3490

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Coldstream Capital Management's JSPR Position: Q2 2025 in Review

Coldstream Capital Management sold out of Jasper Therapeutics (JSPR) in Q2 2025, closing a stake of 38 shares — an estimated $164 sold.

Coldstream Capital Management first reported a position in JSPR in Q1 2025 and held it in 1 quarter. The position peaked at $164 in Q1 2025. 65 funds tracked by Wall St. Rank hold JSPR as of Q2 2025.

  • Coldstream Capital Management reported no remaining Jasper Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 38 Jasper Therapeutics shares in Q2 2025, an estimated $164.
  • Coldstream Capital Management first reported a position in Jasper Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Jasper Therapeutics position peaked at $164 in Q1 2025.
  • 65 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.